Standard Standard

Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease. / Hurt, Catherine S; Alkufri, Fadi; Brown, Richard G et al.
In: Journal of Parkinson's disease, Vol. 4, No. 2, 2014, p. 245-54.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

Hurt, CS, Alkufri, F, Brown, RG, Burn, DJ, Hindle, JV, Landau, S, Wilson, KC, Samuel, M & PROMS-PD study group 2014, 'Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease', Journal of Parkinson's disease, vol. 4, no. 2, pp. 245-54. https://doi.org/10.3233/JPD-130314

APA

Hurt, C. S., Alkufri, F., Brown, R. G., Burn, D. J., Hindle, J. V., Landau, S., Wilson, K. C., Samuel, M., & PROMS-PD study group (2014). Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease. Journal of Parkinson's disease, 4(2), 245-54. https://doi.org/10.3233/JPD-130314

CBE

Hurt CS, Alkufri F, Brown RG, Burn DJ, Hindle JV, Landau S, Wilson KC, Samuel M, PROMS-PD study group. 2014. Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease. Journal of Parkinson's disease. 4(2):245-54. https://doi.org/10.3233/JPD-130314

MLA

VancouverVancouver

Hurt CS, Alkufri F, Brown RG, Burn DJ, Hindle JV, Landau S et al. Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease. Journal of Parkinson's disease. 2014;4(2):245-54. doi: 10.3233/JPD-130314

Author

Hurt, Catherine S ; Alkufri, Fadi ; Brown, Richard G et al. / Motor phenotypes, medication and mood : further associations with impulsive behaviours in Parkinson's disease. In: Journal of Parkinson's disease. 2014 ; Vol. 4, No. 2. pp. 245-54.

RIS

TY - JOUR

T1 - Motor phenotypes, medication and mood

T2 - further associations with impulsive behaviours in Parkinson's disease

AU - Hurt, Catherine S

AU - Alkufri, Fadi

AU - Brown, Richard G

AU - Burn, David J

AU - Hindle, John V

AU - Landau, Sabine

AU - Wilson, Kenneth C

AU - Samuel, Michael

AU - PROMS-PD study group

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Dopaminergic drugs are the primary risk factor for Impulse Control Behaviours (ICB) in Parkinson's disease (PD), others being early-onset disease and gender.OBJECTIVE: This report further explores ICB symptom relationships with motor and mood phenotypes, the complex relationship with dopaminergic medications, and hypothesizes a model with potential clinical implications.METHODS: Data from 500 PD patients were analyzed. Hypersexuality, gambling and shopping behaviour were assessed using selected questions from the Minnesota Impulsive Disorders Interview questionnaire. Local questions assessed hobbyism. Motor characteristics considered were akinetic-rigid/gait disturbance (PIGD) and 'non-PIGD' phenotypes, motor severity, motor progression, and presence/absence of motor fluctuations. Other variables included anxiety, depression, current levodopa and agonist use, age, gender and cognition.RESULTS: Overall, ICB symptom frequency was 17.8%. There was no relationship between PIGD/non-PIGD motor phenotypes and ICB symptoms. Those with ICB symptoms had higher total combined levodopa/agonist equivalent intake, but not current agonist-only equivalent intake. ICB symptoms were reported by 23.1% of those taking combined levodopa and agonist compared to 19.2% on agonist monotherapy and 11.6% levodopa monotherapy. Compared with non-ICB patients, patients with ICB symptoms were more likely to show an anxious mood phenotype, reported more motor fluctuations, and were younger.CONCLUSIONS: Both PIGD and non-PIGD phenotypes are equally affected. Dose-related risk applies to total anti-parkinsonian medication and not just current agonist-only. Anxious mood phenotypes may carry increased risk. A role of anxiety, either as a marker of risk, indirect causal factor, or maintaining factor is incorporated into a preliminary model. We discuss implications for clinical management.

AB - BACKGROUND: Dopaminergic drugs are the primary risk factor for Impulse Control Behaviours (ICB) in Parkinson's disease (PD), others being early-onset disease and gender.OBJECTIVE: This report further explores ICB symptom relationships with motor and mood phenotypes, the complex relationship with dopaminergic medications, and hypothesizes a model with potential clinical implications.METHODS: Data from 500 PD patients were analyzed. Hypersexuality, gambling and shopping behaviour were assessed using selected questions from the Minnesota Impulsive Disorders Interview questionnaire. Local questions assessed hobbyism. Motor characteristics considered were akinetic-rigid/gait disturbance (PIGD) and 'non-PIGD' phenotypes, motor severity, motor progression, and presence/absence of motor fluctuations. Other variables included anxiety, depression, current levodopa and agonist use, age, gender and cognition.RESULTS: Overall, ICB symptom frequency was 17.8%. There was no relationship between PIGD/non-PIGD motor phenotypes and ICB symptoms. Those with ICB symptoms had higher total combined levodopa/agonist equivalent intake, but not current agonist-only equivalent intake. ICB symptoms were reported by 23.1% of those taking combined levodopa and agonist compared to 19.2% on agonist monotherapy and 11.6% levodopa monotherapy. Compared with non-ICB patients, patients with ICB symptoms were more likely to show an anxious mood phenotype, reported more motor fluctuations, and were younger.CONCLUSIONS: Both PIGD and non-PIGD phenotypes are equally affected. Dose-related risk applies to total anti-parkinsonian medication and not just current agonist-only. Anxious mood phenotypes may carry increased risk. A role of anxiety, either as a marker of risk, indirect causal factor, or maintaining factor is incorporated into a preliminary model. We discuss implications for clinical management.

KW - Affect

KW - Aged

KW - Antiparkinson Agents

KW - Cohort Studies

KW - Disruptive, Impulse Control, and Conduct Disorders

KW - Female

KW - Humans

KW - Levodopa

KW - Male

KW - Middle Aged

KW - Movement Disorders

KW - Parkinson Disease

KW - Phenotype

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.3233/JPD-130314

DO - 10.3233/JPD-130314

M3 - Article

C2 - 24366927

VL - 4

SP - 245

EP - 254

JO - Journal of Parkinson's disease

JF - Journal of Parkinson's disease

SN - 1877-7171

IS - 2

ER -